Skip to main content

Table 2 Subgroup analysis of the meta-analysis

From: Efficacy and safety of cinacalcet compared with other treatments for secondary hyperparathyroidism in patients with chronic kidney disease or end-stage renal disease: a meta-analysis

Outcomes Subgroup Number of trials Effect (95% CI) Estimate for overall effect Heterogeneity
Serum PTH concentration USA 5 − 209.57 (− 341.06, − 78.07) P = 0.002 I2 = 83.6%, P < 0.001
Other country 3 −327.13 (− 454.5, − 199.77) P < 0.001 I2 = 79.8%, P = 0.007
Patient median age
<55
5 − 300.73 (− 417.8, − 183.67) P < 0.001 I2 = 67%, P = 0.017
Patient median age
≥55
3 − 211.64 (− 330.57, − 92.72) P < 0.001 I2 = 90.6%, P < 0.001
Sample size <200 3 − 235.15 (− 314.24, − 156.05) P < 0.001 I2 = 0, P = 0.417
Sample size ≥200 5 − 281.23 (− 385.59, − 176.88) P < 0.001 I2 = 87.5%, P < 0.001
Duration of the trial
<24 w
4 − 289.97 (− 435.79, − 144.15) P < 0.001 I2 = 75.5%, P = 0.007
Duration of the trial
≥24 w
4 − 235.23 (− 361.52, − 108.95) P < 0.001 I2 = 86.4%, P < 0.001
Serum phosphate concentration USA 5 −0.14 (− 0.61, 0.32) P = 0.544 I2 = 92.3%, P < 0.001
Other country 4 −0.51 (− 0.73, − 0.29) P < 0.001 I2 = 27.1%, P = 0.249
Patient median age
<55
4 −0.41 (− 0.74, − 0.09) P = 0.013 I2 = 62.2%, P = 0.047
Patient median age
≥55
5 −0.25 (− 0.71, 0.22) P = 0.297 I2 = 92.7%, P < 0.001
Sample size <200 3 − 0.42 (− 0.89, 0.05) P = 0.081 I2 = 68.6%, P = 0.042
Sample size ≥200 6 −0.27 (− 0.66, 0.12) P = 0.175 I2 = 91.3%, P < 0.001
Duration of the trial
<24 w
4 − 0.33 (− 0.58, − 0.09) P = 0.008 I2 = 24.9%, P = 0.262
Duration of the trial
≥24 w
5 −0.30 (− 0.79, 0.19) P = 0.226 I2 = 93.8%, P < 0.001
Receiving dialysis 8 −0.43 (− 0.58, 0.29) P < 0.001 I2 = 32.3%, P = 0.170
Not receiving dialysis 1 0.50 (0.3, 0.7) P < 0.001
Serum calcium phosphorus product USA 4 −4.86 (−10.82, 1.09) P = 0.109 I2 = 94.6%, P < 0.001
Other country 4 −7.15 (−11.88, − 2.41) P = 0.003 I2 = 80.5%, P = 0.002
Patient median age
<55
4 −5.79 (− 10.91, − 0.66) P = 0.027 I2 = 80.4%, P = 0.002
Patient median age
≥55
4 −6.18 (− 11.98, − 0.37) P = 0.037 I2 = 95.1%, P < 0.001
Sample size <200 3 - 4.33 (− 10.96, 2.31) P = 0.201 I2 = 80.1%, P = 0.007
Sample size ≥200 5 − 6.84 (− 11.77, − 1.91) P = 0.007 I2 = 94.2%, P < 0.001
duration of the trial
<24 w
4 −8.26 (− 11.28, − 5.24) P < 0.001 I2 = 48.4%, P = 0.121
duration of the trial
≥24 w
4 −3.87 (−9.85, 2.12) P = 0.206 I2 = 94.9%, P < 0.001
Receiving dialysis 7 −7.29 (−9.77, − 4.81) P < 0.001 I2 = 68.6%, P = 0.004
Not receiving dialysis 1 1.20 (− 0.68, 3.08) P = 0.210
  1. CKD Chronic kidney disease, HD hemodialysis, NA not available, PTH parathyroid hormone, PD peritoneal dialysis